Alpha Cognition, Inc.

Plus, news about Nippon Shinyaku, Atsena, Orna Therapeutics, Ovid Therapeutics, Graviton Bioscience, Eupraxia, Entero Therapeutics, Journey Therapeutics, Theravance Biopharma, Alpha Cognition and Travere Therapeutics: 89bio’s $125M offering: The liver and cardiometabolic biotech is selling shares $ETNB at $8.50 apiece, or about 55 cents below Tuesday’s closing price. Its stock slid nearly 10% on Tuesday. — Kyle LaHucik FDA places partial hold on Kezar study: The company is testing an immunoproteasome inhibitor called zetomipzomib in autoimmune hepatitis. The currently enrolled patients will be allowed to complete the trial, but four patients who are still in the blinded portion cannot proceed to the open-label extension. It’s the second hold for the drug since the start of October when another trial was placed on full clinical hold after four patients died. Topline data are expected in the first half of 2025. — Max Gelman Nippon Shinyaku licenses Atsena’s gene therapy in the US and Japan: Financial details of the deal were not disclosed, though Nippon Shinyaku will reimburse Atsena for continued development work for the rare eye disease treatment, including an expected pivotal study. Atsena also gets to keep the rights to a priority review voucher if it receives one. Nippon Shinyaku plans to market the therapy in the US via its subsidiary, NS Pharma. — Lei Lei Wu Orna cuts more staffers: The circular RNA-focused biotech told Endpoints News in a statement that it “restructured its team” as part of a broader pipeline prioritization, but did not disclose the number of cuts. The drugmaker previously laid off less than 25% of its staff in November 2023 in what it described as a “defensive reduction.” — Ayisha Sharma Ovid, Graviton pause starting Phase 2 trial: The companies are holding back from initiating their study of OV888 in people with cerebral cavernous malformations (CCM) to “evaluate clinical design learnings emerging from competitor” readouts. In September, Recursion Therapeutics’ CCM drug showed strong safety but mixed efficacy in a Phase 2 trial. — Ayisha Sharma Eupraxia touts additional Phase 1b/2a data: The company said that data from two cohorts of the trial, which is investigating EP-104GI as a treatment for eosinophilic esophagitis, showed reductions in the severity, symptoms and extent of the disease. In one cohort, a patient achieved complete histological remission. Eupraxia CEO James Helliwell said that “higher dosing levels are yielding improved patient responses.” — Katherine Lewin Entero’s reverse merger: The company is handing its Nasdaq spot to ADC biotech Journey Therapeutics three months after letting go of nearly all its employees and seeking strategic alternatives. Journey will get 99% of Entero’s equity, and its CEO Henry Ji will lead the combined company. — Kyle LaHucik Theravance forms strategic review committee: In its third-quarter financial results , the company said it would “assess all strategic alternatives,” including those related to its COPD drugs Yupelri and Trelegy. Theravance pulled in $16.9 million in revenue this quarter, but it all came from the Viatris collaboration for Yupelri. Along with announcing the review, Theravance separated the roles of board chair and CEO, naming Susannah Gray as chair while Rick Winningham will continue as CEO. The company made staff and program cuts last year. Its stock $TBPH was up about 11% on Wednesday morning. — Katherine Lewin Alpha Cognition prices $50M upsized public offering: The neuro biotech received a notice of allowance for its patent application covering its Alzheimer’s drug, called Zunveyl, through 2044. The funds from the public offering are expected to go toward the commercialization and launch of Zunveyl, R&D and other commercial and general corporate purposes. Zunveyl scored FDA approval in July. — Katherine Lewin Travere upsized its public offering . It raised a total of $143.8 million. — Jaimy Lee

VANCOUVER, British Columbia--( BUSINESS WIRE )--Alpha Cognition Inc. (Nasdaq: ACOG) (CSE: ACOG) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, today announced the pricing of its upsized public offering of 8,695,653 common shares at a public offering price of $5.75 per share, for gross proceeds of approximately $50 million, before deducting underwriting discounts, commissions, and estimated offering expenses. In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional 1,184,592 common shares to cover over-allotments at the public offering price, less the underwriting discount. All of the common shares are being offered by the Company. The offering is expected to close on November 13, 2024, subject to the satisfaction of customary closing conditions. The Company has received approval to list its common shares on the Nasdaq Capital Market under the symbol “ACOG” and is expected to begin trading on Nasdaq today, November 12, 2024. The Company intends to use the proceeds towards the commercialization and launch of ZUNVEYL TM in Alzheimer’s Disease, further research and development of its pipeline product candidates, continued commercial CMC activities (chemistry, manufacturing, and controls), and for working capital and general corporate purposes. “This offering serves as a tremendous milestone for Alpha Cognition, as we begin the commercialization of our FDA-approved drug, ZUNVEYL, for the treatment of mild-to-moderate Alzheimer’s Disease,” said Michael McFadden, Chief Executive Officer and Director of the Company. "This financing puts our balance sheet in a position of meaningful strength and provides the necessary foundation for a successful commercial launch, with ample runway to scale over the next few years. We are thrilled to welcome a number of new, high-quality investors to our Nasdaq listing, who also see the benefits of ZUNVEYL and the exciting opportunity for our platform.” Titan Partners Group, a division of American Capital Partners, is acting as Sole Bookrunner for the offering. The securities were sold pursuant to a registration statement on Form S-1 (File No. 333-280196) relating to these securities and a related registration statement on Form S-1 MEF that became effective upon its filing in accordance with Rule 462(b) under the Securities Act of 1933, as amended. The Offering is being made only by means of a prospectus. A copy of the final prospectus related to the Offering may be obtained, when available, from Titan Partners Group LLC, a division of American Capital Partners, LLC, 4 World Trade Center, 29th Floor, New York, NY 10007, or via email at prospectus@titanpartnersgrp.com or telephone at (929) 833-1246. In addition, a copy of the final prospectus, when available, relating to the Offering may be obtained via the SEC's website at www.sec.gov . This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Alpha Cognition Inc. Alpha Cognition Inc. is a commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease and Cognitive Impairment with mild Traumatic Brain Injury (“mTBI”), for which there are currently no approved treatment options. ZUNVEYL is a patented drug approved as a new generation acetylcholinesterase inhibitor (AChEI) for the treatment of Alzheimer’s disease, with expected minimal gastrointestinal side effects. ZUNVEYL’s active metabolite is differentiated from donepezil and rivastigmine in that it improves the function of neuronal nicotinic receptors, most notably the alpha-7 subtype, which is known to have a positive effect on cognition. Benzgalantamine is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia, and as an intranasal formulation for Cognitive Impairment with mTBI. Forward-looking Statements This news release includes forward-looking statements within the meaning of applicable securities laws. Except for statements of historical fact, any information contained in this news release may be a forward‐looking statement that reflects the Company’s current views about future events and are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward‐looking statements by the words “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “target,” “seek,” “contemplate,” “continue” and “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward‐looking statements may include statements regarding the potential closing of the Offering, the use of proceeds of the Offering, receipt of regulatory and stock exchange approvals in connection with Offering and completion of the Nasdaq uplisting. Although the Company believes to have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. The Company cannot assure that the actual results will be consistent with these forward-looking statements. These forward‐looking statements speak only as of the date of this news release and the Company undertakes no obligation to revise or update any forward‐looking statements for any reason, even if new information becomes available in the future.

Plus, news about Kymera Therapeutics, Nanoscope, Eupraxia, Alpha Cognition and EyePoint: FDA lifts hold of CARsgen’s CAR-T therapies: The FDA on Thursday lifted a clinical hold on three of CARsgen Therapeutics’ CAR-T therapies. The trials were halted in December due to issues found at the company’s manufacturing facilities in Durham, NC. The drugs — CT053, CT041 and CT071 — are being investigated against BCMA, Claudin18.2 and GPRC5D, respectively. — Anna Brown Ono lets option for itolizumab expire: The company signed an agreement with Equillium in 2022 to potentially purchase an IgG1 monoclonal antibody in graft versus host disease. But Ono decided not to acquire the drug, with Equillium’s stock $EQ closing 37% lower on Thursday. Equillium also reorganized its pipeline and paused enrollment of a Phase 3 study of itolizumab, according to an SEC filing . — Max Gelman Kymera Therapeutics ends oncology work: The biotech will instead focus on its immunology pipeline , which includes STAT6, IRAK4 and TYK2 degrader programs. Two cancer drugs will not proceed past Phase 1 development. Kymera said it is “evaluating partnership opportunities” for them. — Max Gelman Nanoscope’s two-year data for eye disease gene therapy: The program, MCO-010, is being developed for permanent and severe vision loss from advanced retinitis pigmentosa. The high-dose group had a statistically significant improvement in patients being able to read an eye chart after 52 and 76 weeks. There were no serious side effects, and the most commonly reported ones were hypertension in different parts of the eye. — Max Gelman Eupraxia discloses $32M private placement: The Canadian company plans to use the funding to support research into its experimental treatment for eosinophilic esophagitis. — Jaimy Lee Alpha Cognition’s $25M offering: The Vancouver biotech, which makes neurodegenerative disease treatments, also plans to uplist to the Nasdaq . — Kyle LaHucik EyePoint ended up raising $161 million in its upsized public offering. — Jaimy Lee